Kenai Therapeutics

Also Clin0 inherited Parkinson's; INDP-002 RD Parkinson's; RNDP-003 RD young onset Parkinson's

Kenai Therapeutics is using induced pluripotent stem cell (iPSC) technology to develop neuron replacement therapies to cure neurological disorders. With central nervous system disorders, such as Parkinson’s disease, neurons are lost to neurodegeneration. Kenai Therapetics is addressing this by leveraging the Nobel-winning scientific breakthrough of iPSC technology to replace neurons to modify and reverse disease progression. RNDP-001 is their lead candidate for treating Parkinson’s disease. It is an iPSC dopamine progenitor that demonstrated improved survival, innervation and behavior changes in preclinical models of Parkinson’s disease. Kenai Therapeutics is pioneering novel approaches to treating neurological disorders.

Jobs: